Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Director William D. Waddill sold 8,500 shares of the firm’s stock in a transaction dated Friday, January 11th. The shares were sold at an average price of $14.77, for a total value of $125,545.00. Following the completion of the transaction, the director now owns 46,500 shares in the company, valued at approximately $686,805. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
ARWR traded down $0.13 during midday trading on Friday, reaching $14.87. 1,260,344 shares of the company were exchanged, compared to its average volume of 2,029,443. The company has a current ratio of 6.37, a quick ratio of 6.37 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a one year low of $4.77 and a one year high of $22.39. The stock has a market cap of $1.36 billion, a P/E ratio of -22.88 and a beta of 1.96.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.05. Arrowhead Pharmaceuticals had a negative return on equity of 57.18% and a negative net margin of 337.32%. The firm had revenue of $11.26 million for the quarter, compared to analysts’ expectations of $3.73 million. As a group, equities analysts forecast that Arrowhead Pharmaceuticals Inc will post 1.49 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of ARWR. Great West Life Assurance Co. Can bought a new position in Arrowhead Pharmaceuticals during the second quarter worth about $106,000. Stratos Wealth Partners LTD. bought a new position in Arrowhead Pharmaceuticals during the third quarter worth about $123,000. Meeder Asset Management Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $129,000. Macquarie Group Ltd. acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $151,000. Finally, BlueMountain Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $188,000. Hedge funds and other institutional investors own 60.45% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Article: What are CEFs?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.